801 The anti-tumor efficacy of immunogenic chemotherapy is enhanced by the dual A2aR/A2bR antagonist etrumadenant, relieving the necessity for an extended chemotherapy regimen
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.